AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20032543 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-16 weeks of pegylated interferon and ribavirin treatment
Number of subjects: 8
Study 20032543 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of pegylated interferon and ribavirin treatment
Number of subjects: 8
Study 16515966 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand assisted procedure
Number of subjects: 33
Study 16515966 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal procedure
Number of subjects: 33
Study 16515966 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal procedure
Number of subjects: 33
Study 12720508 — intervention group
Group type: COMPARATOR
Intervention: Cold vaccine (no deliberate warming)
Number of subjects: 150
Study 12720508 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed vaccine (37 degrees C incubator)
Number of subjects: 150
Study 12720508 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubbed vaccine (rubbed between palms for 1 minute)
Number of subjects: 150
Study 10934803 — intervention group
Group type: COMPARATOR
Intervention: CEOV therapy (cyclophosphamide, epirubicin, vincristine, etoposide)
Number of subjects: 150
Study 10934803 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOV-CAM therapy (cyclophosphamide, ACNU, methotrexate)
Number of subjects: 150
Study 10934803 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOV-CAM therapy (limited disease)
Number of subjects: 150
Study 10934803 — intervention group
Group type: COMPARATOR
Intervention: CEOV therapy (limited disease)
Number of subjects: 150
Study 10934803 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving thoracic irradiation after response
Number of subjects: 150
Study 10934803 — intervention group
Group type: COMPARATOR
Intervention: CEOV arm (tumor recurrence)
Number of subjects: 150
Study 10934803 — intervention group
Group type: EXPERIMENTAL
Intervention: CEOV-CAM arm (tumor recurrence)
Number of subjects: 150
Study 9346173 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity, low-distance program (E)
Number of subjects: 96
Study 9346173 — intervention group
Group type: COMPARATOR
Intervention: Usual program (C)
Number of subjects: 96
Study 8393760 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization shots on day 0 and day 14 (n = 47)
Number of subjects: 144
Study 8393760 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization shots on day 0 and day 28 (n = 50)
Number of subjects: 144
Study 8393760 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization shots on day 0, 14 and 28 (n = 47)
Number of subjects: 144
Study 8393760 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (after booster shot)
Number of subjects: 144
Study 8393760 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (after first immunization)
Number of subjects: 144
Study 8393760 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (between second and third immunization)
Number of subjects: 144
Study 8393760 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections two weeks apart
Number of subjects: 144
Study 8393760 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 144
Study 30900326 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose caffeine citrate (80 mg/kg)
Number of subjects: 218
Study 30900326 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose caffeine citrate (20 mg/kg)
Number of subjects: 218
Study 29791275 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for advanced care planning
Number of subjects: 35
Study 29791275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 26473766 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals sleeping in public places
Number of subjects: 1008
Study 26473766 — intervention group
Group type: COMPARATOR
Intervention: Individuals sleeping in shelters
Number of subjects: 1008
Study 24709499 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuebijing injection
Number of subjects: 60
Study 22341379 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural tissue management (education, manual therapy, and nerve gliding exercises in 4 treatments over 2 weeks)
Number of subjects: 60
Study 22341379 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural tissue management
Number of subjects: 60
Study 22341379 — intervention group
Group type: COMPARATOR
Intervention: Control (usual activities advice)
Number of subjects: 60
Study 20347506 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine 1000 mg/m(2) days 1 and 8 plus carboplatin AUC 5.5 day 1 (GCb)
Number of subjects: 1135
Study 20347506 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine 1000 mg/m(2) days 1 and 8 plus paclitaxel 200 mg/m(2) day 1 (GP)
Number of subjects: 1135
Study 20347506 — intervention group
Group type: EXPERIMENTAL
Intervention: paclitaxel 225 mg/m(2) plus carboplatin AUC 6.0 day 1 (PCb)
Number of subjects: 1135
Study 20347506 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate for squamous patients
Number of subjects: 1135
Study 20347506 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to progression for squamous
Number of subjects: 1135
Study 20347506 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to progression for non-squamous
Number of subjects: 1135
Study 20347506 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology-by-treatment interaction effect between GCb and PCb
Number of subjects: 1135
Study 18041238 — intervention group
Group type: EXPERIMENTAL
Intervention: Visian Toric Implantable Collamer Lens (TICL)
Number of subjects: 88
Study 18041238 — intervention group
Group type: COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 88
Study 15642068 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD+BG (test)
Number of subjects: 30
Study 15642068 — intervention group
Group type: COMPARATOR
Intervention: EMD (control)
Number of subjects: 30
Study 12360165 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management program (NURS) including individualized lifestyle modification and pharmacologic intervention for 1 year after discharge
Number of subjects: 228
Study 12360165 — intervention group
Group type: COMPARATOR
Intervention: Usual care enhanced with feedback on lipids to primary provider and/or cardiologist (EUC)
Number of subjects: 228
Study 10204826 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise plus diet (R+D)
Number of subjects: 20
Study 10204826 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment control plus diet (C+D)
Number of subjects: 20
Study 7539233 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose danaparoid (intravenous loading dose of 2000 U followed by 2000 U administered subcutaneously twice daily)
Number of subjects: 209
Study 7539233 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (intravenous loading dose of 2500 U followed by dose-adjusted continuous infusion)
Number of subjects: 209
Study 7539233 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose danaparoid
Number of subjects: 209
Study 7539233 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 209
Study 7539233 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (low-dose danaparoid, high-dose danaparoid, unfractionated heparin)
Number of subjects: 209
Study 2138985 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% ketoconazole cream
Number of subjects: 40
Study 2138985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 373942 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (800 mg/day)
Number of subjects: 40
Study 373942 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (3,600 mg/day)
Number of subjects: 40
Study 31627938 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 grams/day of a highly purified omega‐3 product containing eicosapentaenoic acid (EPA)
Number of subjects: 8179
Study 31627938 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximately 1 gram/day of purified fish oil containing 840 mg/day of EPA and docosahexaenoic acid (DHA)
Number of subjects: 8179
Study 30766593 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion at 0.4mcg/kg/hr
Number of subjects: 104
Study 30766593 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil infusion at 0.2mcg/kg/min
Number of subjects: 104
Study 26867000 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective stimulant-like effects
Number of subjects: 82
Study 26867000 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sedative-like effects
Number of subjects: 82
Study 26867000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 23013107 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial laser therapy with the NeuroThera® Laser System
Number of subjects: 1000
Study 23013107 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial laser therapy procedure
Number of subjects: 1000
Study 22777879 — intervention group
Group type: EXPERIMENTAL
Intervention: Various obesity treatments (specific treatments not detailed)
Number of subjects: 191
Study 20361844 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 50
Study 20361844 — intervention group
Group type: COMPARATOR
Intervention: Pulse oximetry
Number of subjects: 50
Study 18386721 — intervention group
Group type: COMPARATOR
Intervention: 1% Propofol-LCT
Number of subjects: 110
Study 18386721 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Propofol-LCT/MCT
Number of subjects: 110
Study 15909273 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled intervention (CCI)
Number of subjects: 230
Study 15909273 — intervention group
Group type: COMPARATOR
Intervention: Control (no CCI)
Number of subjects: 230
Study 15909273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rules-based interpretation (GI)
Number of subjects: 230
Study 15909273 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual phenotype interpretation (VPI)
Number of subjects: 230
Study 11899591 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25 mg) administered twice daily to the treated group
Number of subjects: 52
Study 11899591 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 52
Study 9732095 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 800
Study 9732095 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 800
Study 7653806 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone (0.5 mg/kg) + fentanyl (3 micrograms/kg)
Number of subjects: 50
Study 7653806 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (3 mg/kg) + fentanyl (3 micrograms/kg)
Number of subjects: 50
Study 2567570 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic contrast medium (iohexol)
Number of subjects: 9
Study 795564 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophin releasing hormone (500 mug subcutaneously every 8 h for 4 weeks)
Number of subjects: 10
Study 795564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30592476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (1.5 mg/kg)
Number of subjects: 90
Study 30592476 — intervention group
Group type: COMPARATOR
Intervention: Intranasal fentanyl (2 μg/kg)
Number of subjects: 90
Study 30592476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine
Number of subjects: 90
Study 30592476 — intervention group
Group type: COMPARATOR
Intervention: Intranasal fentanyl
Number of subjects: 90
Study 27883311 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self-efficacy
Number of subjects: 354
Study 27883311 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 10 male partners in the past 6 months
Number of subjects: 354
Study 27883311 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher optimism regarding the effects of HIV treatments on HIV transmission
Number of subjects: 354
Study 27100764 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid testing for Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) diagnosis
Number of subjects: 70
Study 27100764 — intervention group
Group type: COMPARATOR
Intervention: Standard care testing
Number of subjects: 70
Study 24532685 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Nissen fundoplication (ONF)
Number of subjects: 39
Study 24532685 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 39
Study 22112293 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib
Number of subjects: 0
Study 22112293 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study 20851560 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive framing (70% effective)
Number of subjects: 334
Study 20851560 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative framing (30% ineffective)
Number of subjects: 334
Study 20851560 — intervention group
Group type: COMPARATOR
Intervention: Control frame
Number of subjects: 334
Study 20851560 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed valence frames
Number of subjects: 334
Study 17953496 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions in the experimental condition
Number of subjects: 90
Study 17953496 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no implementation intentions)
Number of subjects: 90
Study 16425125 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine plus zidovudine (SD-NVP + ZDV)
Number of subjects: 38
Study 16425125 — intervention group
Group type: COMPARATOR
Intervention: Single-dose nevirapine (SD-NVP) alone
Number of subjects: 38
Study 16425125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (SD-NVP + ZDV and SD-NVP alone)
Number of subjects: 38
Study 12830834 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (ME)
Number of subjects: 10
Study 12830834 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 10
Study 10589810 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic curettes (Universal Perio Soft Scaler)
Number of subjects: 40
Study 10589810 — intervention group
Group type: COMPARATOR
Intervention: Conventional steel curettes
Number of subjects: 40
Study 10589810 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic curettes
Number of subjects: 40
Study 8709689 — intervention group
Group type: COMPARATOR
Intervention: Sting removal by scraping
Number of subjects: 0
Study 8709689 — intervention group
Group type: COMPARATOR
Intervention: Sting removal by pinching
Number of subjects: 0
Study 1650036 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with polymyxin, amphotericin, tobramycin, and intravenous cefotaxime
Number of subjects: 331
Study 1650036 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic therapy (Control)
Number of subjects: 331
Study 1650036 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 331
Study 6846940 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 12
Study 6846940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31476706 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender essential oil in the ostomy bag
Number of subjects: 30
Study 31476706 — intervention group
Group type: COMPARATOR
Intervention: Routine practices about nutrition and stoma care
Number of subjects: 30
Study 28455894 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Treatment Program (CTP)
Number of subjects: 80
Study 28455894 — intervention group
Group type: COMPARATOR
Intervention: Individual Treatment Program (ITP)
Number of subjects: 80
Study 25886615 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training course comprising two face to face 6.5 hour sessions run over two days
Number of subjects: 100
Study 25886615 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group (not receiving MHFA training during the study)
Number of subjects: 100
Study 23701746 — intervention group
Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 1 (0.5 mL AVA + 0.5 mg CPG 7909)
Number of subjects: 105
Study 23701746 — intervention group
Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 2 (0.5 mL AVA + 0.25 mg CPG 7909)
Number of subjects: 105
Study 23701746 — intervention group
Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 3 (0.25 mL AVA + 0.5 mg CPG 7909)
Number of subjects: 105
Study 23701746 — intervention group
Group type: EXPERIMENTAL
Intervention: AV7909 Formulation 4 (0.25 mL AVA + 0.25 mg CPG 7909)
Number of subjects: 105
Study 23701746 — intervention group
Group type: COMPARATOR
Intervention: BioThrax (0.5 mL)
Number of subjects: 105
Study 23701746 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (0.5 mL)
Number of subjects: 105
Study 21392109 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component interventions (class education, free sunscreen samples, written materials)
Number of subjects: 285
Study 21392109 — intervention group
Group type: COMPARATOR
Intervention: Written materials only (subgroup B)
Number of subjects: 285
Study 19962469 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT)
Number of subjects: 320
Study 19962469 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) plus OMT
Number of subjects: 320
Study 19962469 — intervention group
Group type: COMPARATOR
Intervention: CKD patients (both OMT and PCI plus OMT)
Number of subjects: 320
Study 17364078 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational interventions (telephone counselling, self-help course, group psychotherapy)
Number of subjects: 0
Study 17364078 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapies (Riquent, belimumab, mycophenolate mofetil, dehydroepiandrosterone, oestrogen therapy, cholesterol-lowering diet)
Number of subjects: 0
Study 15206062 — intervention group
Group type: COMPARATOR
Intervention: scIL-2 at a dose of 1.5 mIU (n=36)
Number of subjects: 218
Study 15206062 — intervention group
Group type: COMPARATOR
Intervention: scIL-2 at a dose of 4.5 mIU (n=36)
Number of subjects: 218
Study 15206062 — intervention group
Group type: COMPARATOR
Intervention: scIL-2 at a dose of 7.5 mIU (n=37)
Number of subjects: 218
Study 12394945 — intervention group
Group type: EXPERIMENTAL
Intervention: Early high-volume hemofiltration (72-96 L per 24 hrs)
Number of subjects: 106
Study 12394945 — intervention group
Group type: EXPERIMENTAL
Intervention: Early low-volume hemofiltration (24-36 L per 24 hrs)
Number of subjects: 106
Study 12394945 — intervention group
Group type: EXPERIMENTAL
Intervention: Late low-volume hemofiltration (24-36 L per 24 hrs)
Number of subjects: 106
Study 9891536 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (52 cases)
Number of subjects: 116
Study 9891536 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone (14 cases)
Number of subjects: 116
Study 9891536 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality (50 cases)
Number of subjects: 116
Study 9891536 — intervention group
Group type: COMPARATOR
Intervention: Tonsillar NHL (56 cases)
Number of subjects: 116
Study 9891536 — intervention group
Group type: COMPARATOR
Intervention: Non-tonsillar NHL (60 cases)
Number of subjects: 116
Study 9891536 — intervention group
Group type: COMPARATOR
Intervention: Stage I and II non-tonsillar patients
Number of subjects: 116
Study 9891536 — intervention group
Group type: COMPARATOR
Intervention: Tonsillar group
Number of subjects: 116
Study 9891536 — intervention group
Group type: COMPARATOR
Intervention: Non-tonsillar group
Number of subjects: 116
Study 7802176 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask (Intavent)
Number of subjects: 10
Study 7802176 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube (Rüsch)
Number of subjects: 10
Study 2919938 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI) with a spacer
Number of subjects: 36
Study 2919938 — intervention group
Group type: COMPARATOR
Intervention: Updraft-compressor nebulization (UDN)
Number of subjects: 36
Study 4571186 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 5
Study 4571186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30361758 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative high-intensity strength training
Number of subjects: 44
Study 28296957 — intervention group
Group type: EXPERIMENTAL
Intervention: NAV (navigation system)
Number of subjects: 120
Study 28296957 — intervention group
Group type: COMPARATOR
Intervention: CT (conventional procedures)
Number of subjects: 120
Study 26581079 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered trials
Number of subjects: 70
Study 26581079 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with adequate outcome analysis definitions
Number of subjects: 70
Study 26581079 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with multiple primary outcome analyses
Number of subjects: 70
Study 26581079 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials registered prior to patient enrollment
Number of subjects: 70
Study 26581079 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepancy in registered and published outcomes
Number of subjects: 70
Study 26581079 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate registration as per guidelines
Number of subjects: 70
Study 26581079 — intervention group
Group type: COMPARATOR
Intervention: Comparison with psychosomatic and behavioral medicine journals
Number of subjects: 70
Study 26581079 — intervention group
Group type: COMPARATOR
Intervention: Comparison of registered trials
Number of subjects: 70
Study 24153416 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR)
Number of subjects: 504
Study 24153416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt table testing (TT)
Number of subjects: 504
Study 21237708 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft orthosis
Number of subjects: 40
Study 21237708 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-rigid orthosis
Number of subjects: 40
Study 21237708 — intervention group
Group type: COMPARATOR
Intervention: No orthosis (control condition)
Number of subjects: 40
Study 19484680 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Number of subjects: 421